{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/osteoporosis-prevention-of-fragility-fractures/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"8adeb7b7-191a-5ba3-96f4-d25461c0b901","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 96efb7ea-8fb7-48e3-9bf6-a6740d057459 --><h2>Update</h2><!-- end field 96efb7ea-8fb7-48e3-9bf6-a6740d057459 -->","summary":null,"htmlStringContent":"<!-- begin item 3793f145-95ca-4775-b176-74525ce5c3e0 --><!-- end item 3793f145-95ca-4775-b176-74525ce5c3e0 -->","topic":{"id":"9f86812a-068c-512b-a1a4-07fda4301d21","topicId":"a4e2c95c-bf7f-4277-b693-c3b2761380ed","topicName":"Osteoporosis - prevention of fragility fractures","slug":"osteoporosis-prevention-of-fragility-fractures","lastRevised":"Last revised in May 2020","chapters":[{"id":"f651cf3f-ec13-5c52-9121-2dd61c54dc3c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"55fa9b49-e88f-5e9b-8156-01352a4c94b5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a36d9df6-8dba-581c-9361-7b771a120859","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0562cda5-80f8-5d79-83f3-f1233a8060e3","slug":"changes","fullItemName":"Changes"},{"id":"8adeb7b7-191a-5ba3-96f4-d25461c0b901","slug":"update","fullItemName":"Update"}]},{"id":"753ec6fc-9992-587b-870c-2a54cddd30c8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"62fbf7e5-b097-5a47-af2f-56553c8b16fb","slug":"goals","fullItemName":"Goals"},{"id":"e2d42919-7f54-594f-bcb8-06f2625a550f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"eca5799e-0969-539e-b27e-e8ed22c5cc54","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"355020b6-9455-5e78-8a1a-172fc947a117","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3c308a4e-8074-5dca-a9bd-a56405a0595f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"745ec600-96ff-5056-8ab4-7ebb02e5286d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4541ac61-d9f8-5c7e-a415-a2f3b57c3f45","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"36908082-d612-5f9e-8dd3-09d9bc87bf79","slug":"definition","fullItemName":"Definition"},{"id":"127d59dc-ce73-51b5-80c0-d57209058280","slug":"causes","fullItemName":"Causes"},{"id":"4349db35-6c86-5ebc-a13f-6a1dce22e466","slug":"complications","fullItemName":"Complications"},{"id":"710ee28b-5971-5b43-ac4e-22ac6fba154d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c62b535b-c8d0-5ce1-93bb-867c8644eb2f","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"35af4f9e-0536-527c-8b94-94cd5f1fa796","fullItemName":"Management","slug":"management","subChapters":[{"id":"bf661812-0f6f-57a2-b0ab-530b799fc4c4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"85598d9c-79e5-5925-8dee-46b4cd8f2170","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f0656a98-39c4-59de-aebb-3eebb0d8dc40","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"38706564-322f-50d2-a7e2-7fe637b76407","slug":"calcium-colecalciferol-vitamin-d3-preparations","fullItemName":"Calcium and colecalciferol (vitamin D3) preparations"},{"id":"0d9951b1-3165-5af5-9601-e12d45a17a6c","slug":"bisphosphonates","fullItemName":"Bisphosphonates"}]},{"id":"c086cbd6-b967-579e-9768-901abfa8d3ca","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"726389ef-f472-5512-a1bf-bf15159602fd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f476f450-a081-5a31-a23e-7b837233a18e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"393e0faf-da4e-5bd5-b705-179c32a6c50b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b11023db-83b9-5207-b99c-7917bef26190","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0b683807-10ff-54fc-936a-06d71aa6f8d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb240203-2f82-5b14-85ec-55933467aceb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"782a2ad0-e9ec-5fc2-b2e1-95ec79f6a2f8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a36d9df6-8dba-581c-9361-7b771a120859","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"91b13ca9-ded7-5744-a0d0-c3b8885ce45e","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 72d861f5-524e-45cf-88d1-37536aa54341 --><h3>New evidence</h3><!-- end field 72d861f5-524e-45cf-88d1-37536aa54341 -->","summary":null,"htmlStringContent":"<!-- begin item e6e03ccb-f235-4a72-a8a9-6274ab25924d --><!-- begin field ee4c965c-9ac5-414b-ab12-0c791e3026eb --><h3>Evidence-based guidelines</h3><!-- end field ee4c965c-9ac5-414b-ab12-0c791e3026eb --><!-- begin field fdeb16e0-1a1e-4a62-8d28-d7f577f48ea2 --><ul><li>Buckley, L., Guyatt, G., Fink, H.A., et al. (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. <em>Arthritis & Rheumatology</em> <strong>epub ahead of print</strong>. [<a href=\"http://onlinelibrary.wiley.com/doi/10.1002/art.40137/full\" data-hyperlink-id=\"bf572b40-85ae-45b6-b5e7-a993003a3ab7\">Free Full-text</a>]</li><li>NHS England (2017) <em>Supporting routine frailty identification and frailty care through the GP Contract 2017/2018.</em> NHS England. <a href=\"http://www.england.nhs.uk/\" data-hyperlink-id=\"bbdc83f6-5011-4ec0-a9fd-a993003a3c04\">www.england.nhs.</a><a href=\"http://www.england.nhs.uk/\" data-hyperlink-id=\"92e06ff7-c622-4c70-a864-a993003a3c32\">uk</a> [<a href=\"https://www.england.nhs.uk/wp-content/uploads/2017/04/updated-supporting-guidance-frailty-identification-may-17.pdf\" data-hyperlink-id=\"e4c4f186-9b19-4d63-a265-a993003a3c47\">Free Full-text</a>]</li><li>NICE (2017) <em>Osteoporosis: assessing the risk of fragility fracture</em>. National Institute for Health and Care Excellence. <a href=\"http://www.nice.org.uk/\" data-hyperlink-id=\"28aafd9b-0433-488f-b9e1-a993003a3c60\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/guidance/cg146\" data-hyperlink-id=\"38f74064-e7a8-4c44-94ad-a993003a3c99\">Free Full-text</a>]</li><li>NICE (2017) <em>Bisphosphonates for treating </em>o<em>steoporosis</em>. National Institute for Health and Care Excellence. <a href=\"http://www.nice.org.uk/\" data-hyperlink-id=\"f43cf7d8-2e75-443a-bde2-a993003a3cbf\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/guidance/ta464\" data-hyperlink-id=\"99f109fe-743d-40ea-9aae-a993003a3d86\">Free Full-text</a>]</li><li>Qaseem, A., Forciea, M.A., McLean, R.M., Denberg, T.D. (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. <em>Annals of Internal Medicine</em> <strong>epub ahead of print</strong>. [<a href=\"http://annals.org/aim/article/2625385/treatment-low-bone-density-osteoporosis-prevent-fractures-men-women-clinical\" data-hyperlink-id=\"29f94944-ef95-4959-8a3f-a993003a3db7\">Free Full-text</a>].      </li><li>SIGN (2020) <em>Management of osteoporosis and the prevention of fragility fractures.</em> Healthcare Improvement Scotland. <a href=\"/www.sign.ac.uk\" data-hyperlink-id=\"8061a50d-205a-45dc-b703-ac090098620c\">www.sign.ac.uk</a> [<a href=\"https://www.sign.ac.uk/sign-142-management-of-osteoporosis-and-the-prevention-of-fragility-fractures\" data-hyperlink-id=\"2ca974f0-429e-4597-b6a0-abe600b7f8b5\">Free Full-text</a>]                  </li></ul><!-- end field fdeb16e0-1a1e-4a62-8d28-d7f577f48ea2 --><!-- begin field 5f0bddd6-f218-49b3-8324-35bf05b107bf --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 5f0bddd6-f218-49b3-8324-35bf05b107bf --><!-- begin field a352f833-31bc-4cf3-85db-383b128f4c9b --><p>No new HTAs since 1 December 2015.</p><!-- end field a352f833-31bc-4cf3-85db-383b128f4c9b --><!-- begin field 8c9600b6-abeb-4970-82dd-d745ebda4d6a --><h3>Economic appraisals</h3><!-- end field 8c9600b6-abeb-4970-82dd-d745ebda4d6a --><!-- begin field a905711d-03ab-4d7a-942f-5017042573ca --><p>No new economic appraisals relevant to England since 1 December 2015.</p><!-- end field a905711d-03ab-4d7a-942f-5017042573ca --><!-- begin field dfec3fd9-1fcd-41d4-9877-7e37eb80c34f --><h3>Systematic reviews and meta-analyses</h3><!-- end field dfec3fd9-1fcd-41d4-9877-7e37eb80c34f --><!-- begin field b1588f32-f947-411b-81c4-18b688f6d40e --><ul><li>Skjødt, M. K., et al. (2018) <em>Side effects of drugs for osteoporosis and metastatic bone disease. </em>British Pharmacological Society.</li><li>Fatoye, F., Smith, P., Gebrye, T., et al (2019) <em>Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. </em>British Medical Journal. <a href=\"https://bmjopen.bmj.com/\" data-hyperlink-id=\"a1fa8cdd-fd72-46e1-9eac-aa5500d1507b\">www.bmj.com</a> [<a href=\"https://bmjopen.bmj.com/content/9/4/e027049\" data-hyperlink-id=\"b09dd3f5-62fa-44b8-bc6c-aa5500d15084\">Free Full-text</a>]</li></ul><!-- end field b1588f32-f947-411b-81c4-18b688f6d40e --><!-- begin field ba14e833-a884-414f-9b8a-164d680ea4f5 --><h3>Primary evidence</h3><!-- end field ba14e833-a884-414f-9b8a-164d680ea4f5 --><!-- begin field 48a7c5c0-409f-4c83-adf5-204d359ba375 --><p>No new randomized controlled trials published since 1 December 2015.</p><!-- end field 48a7c5c0-409f-4c83-adf5-204d359ba375 --><!-- end item e6e03ccb-f235-4a72-a8a9-6274ab25924d -->","subChapters":[]},{"id":"1cd38aed-3be5-5098-ab27-b6ad0b4c5e72","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 04fb55a3-dee5-453f-ad3c-c32dad2459af --><h3>New policies</h3><!-- end field 04fb55a3-dee5-453f-ad3c-c32dad2459af -->","summary":null,"htmlStringContent":"<!-- begin item f236c54e-73a8-4087-8f77-364e565909d9 --><!-- begin field 19487c48-1551-43c4-a167-6a698d44164f --><p>No new national policies issued since December 2015.</p><!-- end field 19487c48-1551-43c4-a167-6a698d44164f --><!-- end item f236c54e-73a8-4087-8f77-364e565909d9 -->","subChapters":[]},{"id":"b5a21fca-682d-5830-90f7-59b6e0fa5e87","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 2d4570d7-755a-422f-b79e-016bb5ffe9fb --><h3>New safety alerts</h3><!-- end field 2d4570d7-755a-422f-b79e-016bb5ffe9fb -->","summary":null,"htmlStringContent":"<!-- begin item ac824677-6fdd-4b2e-a8f3-23065672e877 --><!-- begin field 8ffc887c-f9dc-4e10-bc55-5cc69ae8e482 --><p>No new safety alerts since 1 December 2015.</p><!-- end field 8ffc887c-f9dc-4e10-bc55-5cc69ae8e482 --><!-- end item ac824677-6fdd-4b2e-a8f3-23065672e877 -->","subChapters":[]},{"id":"be822828-cf61-588d-b6d2-d4eea21699de","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field c4cf3185-33b6-4b75-9b7c-1f09ab194d16 --><h3>Changes in product availability</h3><!-- end field c4cf3185-33b6-4b75-9b7c-1f09ab194d16 -->","summary":null,"htmlStringContent":"<!-- begin item f302e982-6b4f-4ca3-b2ad-8b3c63142b92 --><!-- begin field 5895fa04-9c3f-48a6-ab25-7dc3d0ded117 --><ul><li>Plenachol D3 capsules (colecalciferol, cholecalciferol) are now also licensed for use as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D deficiency. See more <a href=\"https://www.medicines.org.uk/emc/product/5049/smpc\" data-hyperlink-id=\"d6c22367-8148-4ea5-8b66-ac5600a1795c\">here</a>.</li></ul><!-- end field 5895fa04-9c3f-48a6-ab25-7dc3d0ded117 --><!-- end item f302e982-6b4f-4ca3-b2ad-8b3c63142b92 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}